



September 14, 2022

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Sub: Press Release - Dr. Jaidev Rajpal joins Jubilant as Head of the Company's Generics (Formulations) business

Dear Sirs,

We enclose press release pertaining to the appointment of Dr. Jaidev Rajpal as Head of the Company's Generics (Formulations) business.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

Encl: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



Jubilant Pharmova Limited

1A, Sector 16A, Noida - 201301, India

Tel.: +91 120 4361000

www.jubilantpharmova.com

PRESS RELEASE

Noida, Wednesday, September 14, 2022

Dr. Jaidev Rajpal joins Jubilant as Head of the Company's Generics (Formulations) business

Jubilant Pharmova Limited, an integrated global Pharmaceutical Company, today announced that Dr. Jaidev Rajpal will join the Company as Head of its Generics business effective from October 11, 2022. Jaidev is being appointed as Managing Director & CEO of the Company's wholly owned subsidiary, Jubilant Generics Limited which is involved in the development, manufacturing and distribution of formulations to the US and Non-US markets and is also involved in the India Branded Pharmaceuticals business.

Jaidev has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets. He has a track record of delivering business transformation projects. He joins us from McKinsey & Company where he is working as a Partner in the Pharmaceuticals and Life Sciences practice. Jaidev's appointment will help the Company in transforming its Generics business through commercial and operations excellence including portfolio and R&D rebalancing.

With this appointment, Jaidev will take over the Generics business from Mr. Pramod Yadav, who will continue to be the CEO of the Specialty Pharma (Radiopharma and Allergy Immunotherapy) and CDMO-Sterile Injectables businesses.

Commenting on the occasion, **Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman and Managing Director, Jubilant Pharmova Limited** said: "We are extremely pleased to have Jaidev with us in our endeavour to transform our Generics business to supplement performance of the overall Company. We are confident that with his rich experience and expertise in business transformation, Jaidev will add great value to our Generics business."

On the occasion, **Dr. Jaidev Rajpal**, said, "I feel privileged to join Jubilant Generics which is committed to serving patients in India and across the world. Jubilant Generics is planning an exciting transformation journey to meet its objectives of providing highest quality medicines at the lowest cost. I look forward to working closely with the Jubilant team and drive holistic transformation to create value for all stakeholders."

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Pharmova Limited is also involved in manufacturing of Active Pharmaceutical Ingredients from its USFDA approved facility in Nanjangud, India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and



auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

For more information, please contact:

For Investors

Vineet V Mayer / Surajit Pal

Ph: +91 120 436 1103 / 1002

E-mail: vineet.mayer@jubl.com, Surajit.pal1@jubl.com

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

